2-Fluorodeschloroketamine (2-FDCK, also written 2F-DCK or fluoroketamine) is a synthetic dissociative anesthetic of the arylcyclohexylamine class, structurally related to ketamine and deschloroketamine (DCK). It emerged on the research chemical market in the mid-2010s as a legal alternative to ketamine, and rapidly became one of the most popular dissociative RCs owing to its profile of effects that community members describe as sitting between ketamine and DCK — somewhat longer-lasting and more "mind-opening" than ketamine, with a cleaner headspace than DCK.
Like all arylcyclohexylamines, 2-FDCK acts primarily as an NMDA receptor antagonist, producing dose-dependent dissociative effects ranging from mild perceptual alterations at threshold doses through pronounced dissociation, visual distortions, time distortion, and ego dissolution (the "k-hole" equivalent) at high doses. At subanesthetic doses it produces euphoria, music enhancement, and a characteristic dissociative "headspace" that users frequently describe as introspective and thought-provoking. The fluorine substitution at the 2-position of the cyclohexyl ring alters metabolism relative to ketamine, producing a longer duration of action — typically 90 minutes to 3 hours at recreational doses versus 45–90 minutes for ketamine.
Community experience emphasizes that 2-FDCK is substantially more potent by weight than ketamine, with active doses beginning around 10–20 mg insufflated. Compulsive redosing and frequent use carry the same bladder toxicity risks established for ketamine, and this risk is considered a primary harm reduction concern. The substance has been used in social settings (concerts, festivals) at low doses for music enhancement, and in solo introspective settings at higher doses for exploratory experiences.
Safety at a Glance
High Risk- Start Very Low — This Is Not Ketamine by Weight
- Protect Your Bladder
- Toxicity: Acute Toxicity No formal toxicological studies exist for 2-FDCK in humans. Based on structural and pharmacological si...
- Dangerous with: Alcohol, Desomorphine, GBL, GHB (+2 more)
- Overdose risk: Overdose on 2-Fluorodeschloroketamine can range from unpleasant to life-threatening depending on ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 1.5 hrs – 3 hrsoral
Total: 2.5 hrs – 5 hrsHow It Feels
The first sign is a faint heaviness behind the eyes, as though someone has gently placed warm coins on your eyelids. Twenty minutes in and the room begins to feel further away — not visually distorted, but conceptually distant, as if the space between you and the nearest wall has acquired a strange new density. Your legs feel solid but oddly imprecise, like they belong to a mannequin that happens to follow your instructions. There is no rush, no sudden threshold crossing. 2-Fluorodeschloroketamine simply seeps in, patient and unhurried, like fog rolling through a valley at dawn.
The come-up stretches across an hour or more, and this is part of its signature: a slow, methodical dissolution of the ordinary. Sounds take on a hollow, reverberant quality, as though the room has expanded into a cathedral nave. Music becomes architectural — you can feel its scaffolding, the way basslines support melodic arches. Your thoughts remain surprisingly lucid. You can hold a conversation, navigate a room, even read text on a screen, though each action carries a pleasant sense of distance, as if you are operating yourself through a well-designed remote control. The body high is smooth and analgesic: aches you had forgotten about simply vanish, replaced by a clean, neutral warmth that is neither euphoric nor sedating but simply comfortable.
At the peak, which may not arrive until ninety minutes or two hours have passed, the dissociation settles into a plateau that feels remarkably stable. Space becomes elastic — rooms seem to stretch and compress with your breathing, and the boundary between your body and the chair beneath you grows porous. Closed-eye imagery is geometric and orderly: tessellated corridors, lattice structures folding through dimensions you can almost count. There is an intellectual clarity to the experience that sets it apart from heavier dissociatives. You can examine your own thoughts as though they are objects arranged on a table before you, selecting one, turning it over, placing it back. Emotional tone is even and contemplative. The manic edge of the arylcyclohexylamines is entirely absent here.
The plateau holds for hours — three, four, sometimes five — and this duration is both its gift and its demand. It asks for an evening, not a moment. The descent is equally gradual: the world regains its normal proportions by slow degrees, objects reassert their weight and edges, and you find yourself reaching for a glass of water with a hand that once again feels entirely your own. There is a gentle afterglow of mental quietude, a residual sense that the noise of daily cognition has been turned down by a single notch. Sleep, when it comes, is deep and unmarked by dreams.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(13)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(11)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(20)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(1)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Pharmacology
Mechanism of Action
2-FDCK's pharmacology is inferred from its structural similarity to ketamine and deschloroketamine, as no formal pharmacokinetic or receptor binding studies have been published on the compound itself. Like all arylcyclohexylamines, it is understood to act primarily as a non-competitive antagonist at NMDA (N-methyl-D-aspartate) receptors — blocking the ion channel in an open-channel fashion (the "trapping" block mechanism shared with ketamine, PCP, and other dissociatives).
NMDA receptors are ionotropic glutamate receptors that require both glutamate binding and membrane depolarization to open. They play critical roles in synaptic plasticity, learning, and memory consolidation. Non-competitive antagonism of these receptors by 2-FDCK interrupts thalamocortical and corticocortical signaling, producing the characteristic dissociative syndrome: analgesia, amnesia at high doses, perceptual distortion, and at sufficient doses, complete dissociation from sensory input.
Structural Distinctions
2-FDCK differs from ketamine through two structural changes:
- Replacement of the 2-chloro group (on the phenyl ring) with a fluorine atom — fluorine has a similar steric profile but different electronic properties
- Absence of the keto oxygen relative to some analogs (the 2'-oxo position, present in ketamine, is retained)
The net effect is a compound with somewhat altered pharmacokinetics — users and anecdotal reports consistently note a longer duration than ketamine (2–3 hours vs 1–1.5 hours at equivalent effect levels), possibly reflecting different metabolic processing by hepatic cytochrome P450 enzymes.
Tolerance and Dependence
As with ketamine, tolerance to 2-FDCK's subjective effects develops rapidly with repeated use. There is cross-tolerance within the NMDA antagonist class. Physical dependence is possible with frequent use; psychological dependence (compulsive use patterns) is frequently reported by heavy users. The urge to redose is a prominent feature that users must actively manage.
Detection Methods
Standard Drug Panel Inclusion
2-Fluorodeschloroketamine (2-FDCK) is NOT included on standard drug screening panels. Ketamine itself is not part of standard 5-panel or 10-panel drug tests, and analogues like 2-FDCK are even less likely to be detected. Extended panels that include ketamine may or may not cross-react with 2-FDCK depending on the specific immunoassay platform. Most conventional screening methods will return negative results.
Urine Detection
2-FDCK is detectable in urine for approximately 2 to 5 days after a single dose. The compound is structurally analogous to ketamine with a fluorine atom replacing the chlorine, and it is expected to undergo similar metabolic pathways including N-demethylation and hydroxylation. The primary metabolites likely include fluorinated analogues of norketamine and dehydronorketamine. LC-MS/MS methods specifically targeting 2-FDCK and its metabolites are required for reliable detection. Standard ketamine confirmation panels may not include this compound.
Blood and Serum Detection
Blood detection windows are approximately 12 to 48 hours. Pharmacokinetic data is limited to case reports and in vitro metabolism studies. Active blood concentrations are expected to be in the low to moderate nanogram-per-milliliter range, comparable to ketamine.
Hair Follicle Detection
Hair analysis for 2-FDCK is theoretically feasible using LC-MS/MS methods but has not been widely validated. Detection windows of up to 90 days are expected based on structural similarity to ketamine.
Confirmatory Methods
LC-MS/MS is the preferred confirmatory method. The fluorine atom provides a useful distinguishing marker from ketamine in mass spectrometric analysis. The compound must be specifically included in the analytical panel, and reference standards are available from research chemical suppliers and forensic chemistry distributors.
Reagent Testing
The Marquis reagent produces no reaction with 2-FDCK. The Mandelin reagent may produce a faint orange color. The Morris reagent (potassium thiocyanate and cobalt thiocyanate) produces a pink to red-brown color with arylcyclohexanone compounds including 2-FDCK and ketamine, helping distinguish them from non-dissociative compounds. Fentanyl test strips are strongly recommended for any product obtained from unregulated sources.
Interactions
| Substance | Status | Note |
|---|---|---|
| Alcohol | Dangerous | — |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| GBL | Dangerous | — |
| GHB | Dangerous | — |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Opioids | Dangerous | — |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-MeO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-MeO-PCMo | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| Benzodiazepines | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 25E-NBOH | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 2C-T | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 2C-T-2 | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Development and Emergence
2-Fluorodeschloroketamine first appeared on the research chemical market in the mid-2010s, likely around 2015–2016. Its emergence coincided with a broader wave of ketamine analogs developed as chemists sought to circumvent evolving drug analogue legislation in various jurisdictions. The fluorine-for-chlorine substitution was a common strategy to produce structurally distinct compounds with similar pharmacological profiles.
Market Position
2-FDCK rapidly distinguished itself from other ketamine analogs by offering a profile that many users found superior to alternatives: cleaner than DCK in some accounts, longer-lasting than ketamine, and with what users described as a more "mindful" or introspective quality. It became particularly popular in European harm reduction and psychedelic communities, where it circulated as a ketamine substitute. Community discussions on platforms like Reddit's r/researchchemicals show consistent engagement with 2-FDCK across the late 2010s and into the 2020s.
Legal Status
2-FDCK occupies a legally ambiguous position in many jurisdictions. In the United Kingdom, it falls under the Psychoactive Substances Act 2016. Various other countries have moved to schedule it explicitly. In the United States it exists in a grey area, potentially covered by federal analogue act provisions but not explicitly scheduled. Its legal status varies significantly by country and continues to evolve.
Harm Reduction
Start Very Low — This Is Not Ketamine by Weight
2-FDCK is significantly more potent than ketamine by weight. Community experience consistently reports that doses which seem equivalent to ketamine in volume produce considerably stronger effects. A recommended starting dose for new users is 10–15 mg insufflated or 20–30 mg oral. Do not use ketamine dose references directly.
Protect Your Bladder
This is the primary long-term harm reduction concern. Evidence from ketamine users is clear:
- Limit frequency — Do not use more than once per week; ideally once per month or less
- Stay hydrated before and after use
- Monitor for symptoms — pain, urgency, reduced flow, blood in urine; stop immediately and see a doctor if these occur
- Cessation resolves early-stage damage — early bladder inflammation is reversible if use stops promptly
Never Combine with Depressants
Combining 2-FDCK with alcohol, opioids, benzodiazepines, or GHB dramatically increases the risk of respiratory depression and unconsciousness. Community reports describe this as one of the most dangerous combinations in the dissociative space. If using in a social context, ensure sober companions are present and aware.
Set Up a Safe Physical Space
The level of motor impairment and loss of situational awareness at dissociative doses means the physical environment matters enormously:
- Use lying down on a surface where you cannot fall or injure yourself
- Remove objects that could cause harm
- Do not combine with activities requiring coordination (driving is absolutely prohibited)
- Have a sober sitter present for high-dose explorations
Manage Redosing
The urge to redose before the previous dose has worn off is a well-documented pattern. Set a timer for the expected duration (2.5–3 hours for a modest dose) and commit to not redosing until it has elapsed. Compulsive redosing is the primary route to both acute harm and long-term bladder damage.
Test Your Substance
Reagent testing with a Marquis reagent (orange-to-red with arylcyclohexylamines) can help confirm substance class. Fentanyl test strips should be used given the prevalence of contaminated research chemical supplies.
Toxicity & Safety
Acute Toxicity
No formal toxicological studies exist for 2-FDCK in humans. Based on structural and pharmacological similarity to ketamine, acute toxicity is expected to be relatively low — respiratory depression is possible at very high doses (particularly when combined with other CNS depressants) but is not the primary risk at typical recreational doses. Cardiovascular stimulation (elevated heart rate and blood pressure) occurs as with ketamine and other arylcyclohexylamines.
Urological/Bladder Toxicity
The most clinically significant toxicity risk is ketamine-associated cystitis and urological damage. Ketamine causes a distinctive and potentially irreversible inflammatory syndrome affecting the bladder, ureters, and kidneys with frequent use — characterized by severe bladder pain, reduced bladder capacity, urinary urgency and frequency, and in serious cases hydronephrosis and renal damage. Because 2-FDCK shares the arylcyclohexylamine scaffold and similar urinary metabolites, this risk is presumed to apply equally. Community harm reduction resources universally identify bladder toxicity as the primary chronic risk.
Warning signs of bladder damage: pain on urination, blood in urine, urgency, reduced urine volume, pelvic pain. Any of these symptoms require immediate cessation of use and medical evaluation.
Psychological Risks
- Acute panic and confusion — particularly at high doses or with unexpected intensity
- Psychological dependence — frequent "k-hole" chasing is a documented pattern
- Memory impairment — at recreational doses, short-term memory is significantly impaired; with chronic heavy use, lasting cognitive effects are possible
- Dissociative-induced accidents — profound motor impairment and loss of situational awareness at dissociative doses creates significant injury risk
Drug Interactions
- CNS depressants (alcohol, benzodiazepines, opioids, GHB) — significantly increases risk of respiratory depression; avoid or use extreme caution
- Stimulants — increases cardiovascular strain
- MAOIs — risk of serotonin syndrome given SERT inhibition properties of some arylcyclohexylamines; avoid
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Overdose on 2-Fluorodeschloroketamine can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Austria:** 2-Fluorodeschloroketamine is illegal to possess, produce and sell under the NPSG. (Neue-Psychoaktive-Substanzen-Gesetz Österreich)
Canada:** 2-Fluorodeschloroketamine is not specifically listed in the Controlled Drugs and Substances Act (CDSA) but could be considered controlled under schedule I: "14 Phencyclidine (1-(1-phenylcyclohexyl)piperidine), its salts, derivatives and analogues and salts of derivatives and analogues, including: (1) Ketamine . . ." It could presumably be considered an analogue of PCP due to its structural similarity to ketamine.
Czech Republic:** 6-APB is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.)
Germany:** 2-Fluorodeschloroketamine is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Italy:** 2-Fluorodeschloroketamine is a Schedule I (Tabella I) controlled substance.
Latvia:** 2-Fluorodeschloroketamine is illegal in Latvia.
Switzerland:** 2-Fluorodeschloroketamine is a controlled substance specifically named under Verzeichnis E.
Turkey:** 2-Fluorodeschloroketamine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** 2-Fluorodeschloroketamine is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 2-Amino-2-phenylcyclohexanone substituted in the phenyl ring with a halide substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Responsible use
Designer drug
Deschloroketamine (O-PCM)
2-Fluorodeschloroketamine (Wikipedia)
2-Fluorodeschloroketamine (Isomer Design)
The Big & Dandy 2-Fluoroketamine Thread (Bluelight)
Experience Reports (2)
Tips (8)
Never use 2-Fluorodeschloroketamine near water (bathtubs, pools, lakes). Dissociation and water are a deadly combination. Loss of body coordination and awareness while near water has caused drownings.
Like ketamine, frequent use of 2-FDCK may pose risks to urinary tract health. Limit use frequency and stay well hydrated. Take extended breaks between sessions to minimize potential bladder and kidney damage.
2-FDCK (2-Fluorodeschloroketamine) produces effects similar to ketamine but with a notably longer duration and slightly less potency. It is the most commonly available ketamine analogue among research chemicals.
If insufflating 2-Fluorodeschloroketamine, start with a small bump and wait 15-20 minutes to assess effects before taking more. Onset via insufflation is faster than oral, but full effects still take time to manifest.
Do not combine 2-Fluorodeschloroketamine with other CNS depressants (alcohol, opioids, benzodiazepines). Dissociatives already depress breathing and cardiovascular function. Adding other depressants creates dangerous respiratory depression.
Compared to ketamine, 2-FDCK requires slightly higher doses to reach equivalent effects. A typical intranasal dose ranges from 50-150mg for moderate effects. The hole dose is considerably higher than ketamine, around 200-300mg.
Community Discussions (1)
See Also
References (3)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- 2-Fluorodeschloroketamine - TripSit Factsheet
TripSit factsheet for 2-Fluorodeschloroketamine
tripsit - 2-Fluorodeschloroketamine - Wikipedia
Wikipedia article on 2-Fluorodeschloroketamine
wikipedia